Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:57:24.511Z.
Calculation as of: 2026-10-06T17:57:24.511Z.
Quote observation: 2026-10-06T17:55:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f4a2befa970cab8c9956b6d8c2bddfeceb0bcb8bde8cbc5a5c0f5a0c0e258424
PEG RATIO
N/A
Monopar Therapeutics Inc.
Market Cap
$534.45M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $534.45M | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $531.17M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $534.91M | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $530.02M | N/A |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $536.98M | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $538.62M | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $529.90M | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $520.57M | N/A |
| Altimmune, Inc. (ALT)vs › | $516.33M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
